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Abstract
In the past, microarray studies have been criticized due to noise and the limited overlap between gene signatures. Prior
biological knowledge should therefore be incorporated as side information in models based on gene expression data to
improve the accuracy of diagnosis and prognosis in cancer. As prior knowledge, we investigated interaction and pathway
information from the human interactome on different aspects of biological systems. By exploiting the properties of kernel
methods, relations between genes with similar functions but active in alternative pathways could be incorporated in a
support vector machine classifier based on spectral graph theory. Using 10 microarray data sets, we first reduced the
number of data sources relevant for multiple cancer types and outcomes. Three sources on metabolic pathway information
(KEGG), protein-protein interactions (OPHID) and miRNA-gene targeting (microRNA.org) outperformed the other sources
with regard to the considered class of models. Both fixed and adaptive approaches were subsequently considered to
combine the three corresponding classifiers. Averaging the predictions of these classifiers performed best and was
significantly better than the model based on microarray data only. These results were confirmed on 6 validation microarray
sets, with a significantly improved performance in 4 of them. Integrating interactome data thus improves classification of
cancer outcome for the investigated microarray technologies and cancer types. Moreover, this strategy can be incorporated
in any kernel method or non-linear version of a non-kernel method.
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Introduction
Patients with similar clinical and pathological characteristics
such as age, tumor size, lymph node status and grade often differ
in clinical outcome and therapy response. Patients for who these
traditional diagnostic and prognostic tools fail can potentially be
discerned with microarray technology. This technology investi-
gates the transcriptomic make-up of a tumor in one experiment. A
decade ago, it was first used in cancer studies to classify tissues as
cancerous or non-cancerous [1–2] and has since emerged as a
popular tool to study different cancer types and outcomes [3–6].
Currently within the domain of cancer, microarray technology has
earned a prominent place for its capacity to characterize the
underlying tumor behavior in detail, leading to an improved
diagnostic and prognostic capability. The earliest and most
exhaustive efforts have been accomplished for breast cancer [7].
In this manuscript, we aim to improve the predictive power in
diagnosis and prognosis of cancer with gene expression data as
predictors, by incorporating side information about interactome
networks in kernel methods.
In the above mentioned studies, genes were treated as single
entities without regard to their neighbors in the interactome
network consisting of a wide variety of interaction pairs such as
protein-protein (PPI), domain-domain (DDI) and microRNA-
mRNA interactions. In Figure 1, a simplified visualization of the
mTOR pathway and its regulating pathways is depicted,
representing a typical network related to oncogenesis. Several
components of these pathways are deregulated in a broad
spectrum of human cancers. In this example, the mTOR pathway
is switched on either when expression of RAS is reduced due to a
mutation or when the tumor suppressor gene PTEN is inactive.
Ideally one wants a classifier that does not make a distinction
between both situations. Moreover, the importance of networks
instead of individual genes has already been demonstrated by the
low gene overlap between prognostic gene signatures in breast
cancer but high overlap in relevant pathways [8], with
proliferation being the most important common driving force
[9]. Genes with similar functions but active in alternative pathways
should be taken into account to improve classification perfor-
mance. Such complementary pathways in which a signal can be
propagated through two or more parallel paths have extensively
been shown to exist. A well known example shared between the
majority of cancer types is p53-mediated apoptosis [10]. A
multitude of mechanisms for apoptosis are triggered by the tumor
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10225suppressor gene p53, among them two distinct apoptotic signaling
pathways. Independent on the specific pathway that causes
inactivation of p53, cancer patients in which apoptosis takes place
should be marked as similar with regard to the expression of those
genes involved in p53-mediated apoptosis. As will be shown, our
method exploits such complementary relations between paths by
considering second order interactions between genes, available in
external databases.
Although gene expression profiles have shown to improve
standard tools on clinical and histopathological parameters, the
transcriptome is not the only omics layer that reflects the
molecular biology of a disease. Many omics layers such as
proteomics and metabolomics are interconnected and potentially
equally important. We previously presented a kernel-based
approach for clinical decision support in which many genome-
wide data sources can be combined [11]. Models based on
multiple omics layers outperformed the models that were based on
one single data set. In the majority of current studies, however,
only microarray data are available. In addition, microarray studies
have been subject to several criticisms and concerns. Microarray
data suffer from a low signal-to-noise ratio, the number of tumor
samples used for training and validation are often limited, and
gene signatures constructed for similar prediction tasks exhibit
very low overlap due to their instability and dependence on the
choice of the training samples [12–13]. It is therefore useful to
expand classification models with gene-related information.
There have been efforts in studying the combined use of gene
expression data with biological networks; however, almost all
within the gene space for the purpose of functional annotation.
Vert and Kanehisa [14] extracted active pathways from gene
expression data by using the metabolic network from the KEGG
database as prior knowledge. Both the metabolic network and the
microarray data were represented as a gene6gene kernel matrix.
They were combined in feature space with a generalized form of
canonical correlation analysis to learn a semantic representation
independent of the two views. Hanisch and colleagues [15]
proposed a variant of hierarchical clustering with an increased
stability and biological plausibility of the obtained clusters,
interpretable as co-regulated pathways. This was obtained by
combining a distance function derived from gene expression data
and one based on a biological network such as KEGG. Li and Li
[16] went one step further by incorporating a priori network
information into regression analysis for the identification of genes
and subnetworks related to diseases or other biological processes.
They considered the Laplacian matrix of the network as penalty
term in a general regression framework.
These methods all focus on genes, while the aim of our work is
to incorporate interactome information to improve classification
for cancer patients. Many databases on different aspects of the
interactome, of which an exhaustive overview is given in [17], are
made freely available to the research community. We will refer to
these databases as secondary data sources. It would be useful to expand
classification models with these sources in the form of the human
interactome. PPI networks have recently been introduced to
extract subnetworks of interacting proteins or to identify
deregulated molecular interactions, evolving from a pathway-
based to a protein-network-based approach [18–21]. Rapaport
and colleagues [22] applied similar ideas to differentiate irradiated
from non irradiated yeast strains, by including a priori pathway
knowledge in the analysis of gene expression data. The high-
frequency components in the data were removed with respect to
the topology of the gene network, after which the smoothed data
was used for classification. Their approach was based on the
assumption that low-frequency components in gene expression
data contain most biologically relevant information. We, however,
will not restrict our analysis to this hypothesis of similar gene
expression levels for neighboring genes on the network.
The previously described approaches only focused on one
protein-related source. A single source, however, is not necessarily
optimal for all cancer-related prediction challenges. In this
contribution, we will not limit our strategy solely to pathways or
PPIs. Multiple secondary data sources can be extracted from
databases, such as KEGG [23], REACTOME [24] and OPHID
[25] (for an overview see Table 1). These sources contain gene-
related information at other levels of biological regulation than
Figure 1. Complementary pathway information and its incor-
poration in the calculation of patients’ similarity. Patients with
the same phenotype can be genotypically different since alternative
trajectories in a pathway are activated or repressed. Ideally, one wants a
classifier that does not make a distinction between alternative
pathways. Suppose patients A and B both have breast cancer. However,
patient A is characterized by repression of RAS while PTEN is silenced in
patient B [72]. When building a model to distinguish breast cancer
patients from control samples, the calculated similarity between
patients A and B should be high. When calculating the pairwise
gene-product (that is, inner product) between these patients however,
they appear to be rather dissimilar with an empirical kernel value of
0.16 due to the different expression for the genes RAS and PTEN. A more
accurate similarity measure would be obtained by considering second
order interactions between genes. Genes that are known to interact are
assigned a larger weight in the calculation of patients’ similarity. Such
interactions are first identified based on, for example, shared pathway
membership obtained from the KEGG database. This is followed by an
exhaustive product between patients’ expression profiles that takes
gene links into account, weighted according to gene neighborhood in
graphs constructed from databases such as KEGG. This will empirically
increase the kernel value to 0.74.
doi:10.1371/journal.pone.0010225.g001
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microarray-based cancer classification, we investigated how to
combine these sources with a patient-based kernel matrix and
present a method that is able to incorporate any type of
interactome data in the classification process. Where with kernel
methods similarity between patients is traditionally calculated with
a similarity measure based on the patients’ gene expression
profiles, interactome data from secondary data sources can be used
to improve the method how patient similarities are calculated. At
the same time, we hypothesize to improve classification perfor-
mance. This is motivated by the principle that in patients within
the same cancer-subgroup, different genes from the same pathway
can be expressed, making single-gene markers not ideal (see
Figure 1). Furthermore, because the relevance of the databases for
each specific problem is not known beforehand and irrelevant
databases may worsen the results, we present multiple well-
considered schemes for combining the information from second-
ary data sources.
Results
Kernel Methods, a powerful class of methods for pattern
analysis, have become a standard tool in data analysis,
computational statistics and machine learning applications due
to their reliability, accuracy and computational efficiency [26].
Although the idea of secondary data incorporation is applicable to
any kernel method or method that can be kernelized, we present
results for the weighted Least Squares Support Vector Machine
(LS-SVM), a method for supervised classification that takes the
typical unbalance in many two-class problems into account
[27–29].
The considered microarray data sets
For this contribution, we mainly focused on breast cancer
because it is one of the most extensively studied cancer types for
which many microarray data sets are publicly available. In
addition, data sets on ovarian cancer, prostate cancer and diffuse
large-B-cell lymphoma were included. Table 2 gives an overview
of the 16 studied data sets with information on outcome,
microarray platform and number of included samples and genes.
These studies cover a wide range of predictable, cancer-related
outcomes such as response, relapse, metastasis and survival. We
took into account the low signal-to-noise ratio of microarray data
and included the 5000 most varying genes (see materials and
methods section).
Interactome data as prior biological knowledge
The human interactome is the compendium of all stable,
transient, direct and indirect physical interactions between
proteins in molecular machines and pathways in an active cell.
Table 1. Secondary data sources.
secondary data source type of pathway resource definition gene pairs # gene pairs release reference
1 KEGG metabolic pathways genes of which the proteins
belong to the same pathway
609.269 49.0 [23]
2 HumanCyc metabolic pathways genes of which the proteins
belong to the same pathway
12.314 12.0 [39,40]
3 EHMN metabolic pathways genes of which the proteins
belong to the same pathway
198.876 / [38]
4 REACTOME metabolic pathways,
signaling pathways
genes involved in the same
reaction or complex
722.508 28 [24]
5 OPHID protein-protein interactions,
genetic interaction networks
genes of which the proteins
interact
221.674 1.71 [25]
6 BioGRID protein-protein interactions genes of which the proteins
interact
40.812 2.0.54 [42]
7 STRING protein-protein interactions experimentally determined gene
interactions
315.686 8.1 [48]
8 DOMINE domain-domain interactions genes with proteins interact-
ing via a domain-domain interaction
18.213.973 1.1 [49]
9 UniDomInt domain-domain interactions genes with proteins interact-
ing via a domain-domain interaction
20.506.327 Aug ’09 [50]
10 PROSITE protein families and domains genes with one or multiple
protein domains, families or
functional sites in common
6.267.453 20.0 [51]
11 Pfam protein families and domains genes with one or multiple
protein domains or families
in common
3.649.554 23.0 [52]
12 miRBase transcription factors, gene
regulatory networks
genes targeted by the same
miRNA
6.819.380 5 [53]
13 miRNAmap transcription factors, gene
regulatory networks
genes targeted by the same
miRNA
28.120.039 2 [54]
14 microRNA.org transcription factors, gene
regulatory networks
genes targeted by the same
miRNA
13.207.828 Sept ’08 [56]
15 TargetScan transcription factors, gene
regulatory networks
genes targeted by the same
miRNA
8.580.619 5.1 [57]
doi:10.1371/journal.pone.0010225.t001
Graph Encoded Interactome Data
PLoS ONE | www.plosone.org 3 April 2010 | Volume 5 | Issue 4 | e10225For cancer, much biological knowledge and pathway information
is available in databases on different aspects of biological systems
[17]. A distinction can be made between protein-protein
interactions (PPI), domain-domain interactions (DDI), metabolic
pathways, signaling pathways, transcription factors, gene regula-
tory networks and protein-compound interactions. Table 1 gives
an overview of the 15 considered secondary data sources, with the
type of pathway information contained in each of them, the
definition of links between genes, and the number of extracted
gene pairs. A more detailed description can be found in the
materials and methods section.
Representation of interactome data based on spectral
graph theory
To incorporate the previous described secondary data sources in
a kernel framework for microarray-based cancer classification
presented in Figure 2, the databases were converted into graphs
from which the corresponding Laplacian matrix can be derived
(step 1 in Figure 2). The pseudoinverse of the Laplacian [30], from
now on referred to as G-matrix, was used to represent similarity
between pairs of genes. With this graph-based approach, both
direct and indirect connections between genes, and thus their
neighborhood in the human interactome are taken into account.
Genes that do not belong to the same pathway but are connected
to a same subset of genes, for example, are assigned a positive
coefficient in the secondary G-matrix. These matrices were
incorporated in the calculation of patient similarity (step 2 in
Figure 2). This corresponds to replacing the standard inner
product by a quadratic form defined upon G
21 (xTG{1x), and is
interpretable as a weighted version of the standard inner product.
An example is presented in Figure 1.
To get an idea about the extra information that is added by the
secondary data sources with respect to the standard inner product,
Table 3 shows the median (25
th–75
th percentile) number of second
order interactions included in each of the 15 secondary data
sources. These numbers slightly vary per source as the 5000 most
varying genes selected from each microarray data set differ. The
larger amount of second order interactions in the G-matrices with
respect to the Laplacian matrices shows that the network
neighborhood is captured by taking the pseudoinverse of the
Laplacian.
Selection of outstanding secondary data sources
To reduce the set of considered secondary data sources to the
ones that are relevant across multiple cancer types and usable for
multiple outcomes, 10 out of 16 microarray data sets were
randomly selected for training, indicated in Table 2. This
reduction in number of secondary data sources is represented in
Figure 2 as step 4. For the 10 training data sets, the data were
randomly split into 10 folds. Five folds were used for model
building based on each individual secondary data source, while 2
folds served for validation (the remaining 3 folds are used later for
the combination of multiple models). To obtain a good estimate
for the generalization error, this procedure was repeated 200
times. To objectively select those secondary data sources that
performed well for the training microarray data sets, models built
on an individual secondary data source with a better average
performance than the baseline model (without inclusion of
secondary data) were given a decreasing score starting from 15
for the best model. Models that performed worse than baseline
were given the score 0. Adding those scores for each secondary
data source over all training sets highlighted three outstanding
Table 2. Microarray data sets.
Data set cancer type Outcome Platform
# samples
(neg/pos) # genes
T1 Berchuck [5] OC Binary survival (short,=
3 yrs vs. long .7 yrs)
U133a 53 (29/24) 12633
V1 Bild [33] OC Binary survival (short,=
3 yrs vs. long .3 yrs)
U133a 133 (88/45) 11911
V2 Chin [6] BC Distant recurrence (no vs. yes) U133av2 129 (102/27) 12633
T2 Hess [73] BC Pathologic response (RD vs. CR) U133a 133 (99/34) 12633
V3 Huang 1 [4] BC Disease recurrence (no vs. yes) U95av2 52 (34/18) 8740
V4 Huang 2 [4] BC Relapse (no vs. yes) U95av2 80 (53/27) 8740
T3 Ivshina [74] BC Local, regional or distant
recurrence (no vs. yes)
U133a+b 249 (160/89) 18001
V5 Miller [75] BC Death from BC (no vs. yes) U133a+b 236 (181/55) 18001
T4 Pittman 1 [76] BC Relapse (no vs. yes) U95av2 158 (95/63) 8740
V6 Pittman 2 [76] BC Loco-regional recurrence (no vs. yes) U95av2 158 (132/26) 8740
T5 Pittman 3 [76] BC Distant metastasis (no vs. yes) U95av2 158 (108/50) 8740
T6 Rosenwald [34] DLBCL Overall survival (short,4 yrs vs.
long .=4 yrs)
Lymphochip 220 (118/102) 6707
T7 Singh [3] PC Tumor status (normal vs. tumor) U95av2 102 (50/52) 8193
T8 Sotiriou 1 [77] BC Relapse (no vs. yes) U133a 187 (120/67) 12633
T9 Sotiriou 2 [77] BC Distant metastasis (no vs. yes) U133a 179 (139/40) 12633
T10 Wang [35] BC Metastasis within 5 yrs (no vs. yes) U133a 276 (183/93) 11911
T, training data set; V, validation data set.
BC, breast cancer; OC, ovarian cancer; DLBCL, diffuse large-B-cell lymphoma; PC, prostate cancer.
RD, residual disease; CR, complete response.
doi:10.1371/journal.pone.0010225.t002
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Table 4). Only these three databases were used for the remaining
data sets.
The mutual information (MI) between the models based on one
of the three selected secondary data sources was on average 0.376,
varying from 0.174 to 0.607 for the 10 training data sets and
indicating certain degree of independence between these sources.
No relationship was found between MI and the increase in
performance with respect to baseline. Seven of the 10 training
microarray data sets are from breast cancer (see Table 2).
However, as can be seen from Table 4, the increase in
performance caused by the three selected secondary data sources
was not limited to breast cancer. KEGG performed well for all
cancer types, OPHID resulted in a better performance for breast
cancer, ovarian cancer and lymphoma, while microRNA.org led
to an increased performance for both breast and prostate cancer.
Based on the training data sets, the data sources STRING and
TargetScan seemed to be specific to breast cancer. Finally, there
were no databases that simultaneously led to an improved
performance for the same training data sets.
Combination of multiple classifiers
Because the relevance of these three sources for each specific
classification task is not known beforehand, the three correspond-
ing individual classifiers were combined at a second level (step 5 in
Figure 2). Three types of combination rules were considered: 1)
fixed rules for which no training is required (that is, mean and
median), 2) simple trained rules for which the influence of each
model on the final prediction is determined by their individual
training performance or for which the optimal combination of
individual models is obtained with an exhaustive search, and 3)
more advanced models, being naı ¨ve Bayes, logistic regression and
linear discriminant analysis. For each of the 200 experiments, the
last two types of combination rules were trained on 8 folds (that is,
including the 5 folds upon which each model was built expanded
with 3 untouched folds) and validated on the remaining 2 folds.
The global workflow consisting of the graph representation of the
secondary data sources, the incorporation into the calculation of
patient similarities, model building, the selection of the relevant
secondary data sources, the combination of relevant models and
validation is provided in Figure 2.
Incorporation of the three outstanding secondary data
sources outperforms the baseline models
The results for the 10 training microarray data sets are shown in
Figure 3 and Table 5. The five bars per data set represent the
mean area under the receiver operating characteristic curve
(AUC) values for the following models: 1) the baseline model built
on the microarray data only, 2) the model based on the secondary
data source with the best performance (KEGG, OPHID or
microRNA.org), 3) the combination of models according to the
best fixed rule, 4) the combination according to the best trained
rule, and 5) the combination of individual models using the best
advanced approach. Figure 4a provides an overview of the
performance of the three selected secondary data sources for all
training data sets. As the prediction accuracy is evaluated by
applying our 10-fold approach 200 times, the 200 test AUC values
of the baseline model were compared with the 200 test AUC
values of the other considered models using the one-sided paired-
sampled t-test. The p-values for these comparisons are shown per
Table 3. Characteristics of the Laplacian and G-matrices.
Secondary
data source
Laplacian: median
# gene pairs
Laplacian: 25
th–
75
th percentile
G-matrices: median
# gene pairs
G-matrices: 25
th–
75
th percentile
1 KEGG 69.870 41.771–99.310 5.553.761 4.950.232–6.473.276
2 HumanCyc 533 298–752 4.616.183 4.548.199–5.524.069
3 EHMN 5.416 3.339–11.847 9.356.394 8.954.741–10.040.781
4 REACTOME 43.611 27.716–59.786 6.453.263 4.585.327–7.725.010
5 OPHID 5.261 2.783–9.601 10.821.416 9.713.765–11.068.831
6 BioGRID 1.995 1.067–3.613 11.047.443 9.744.897–11.811.681
7 STRING 4.327 2.531–8.512 10.563.906 10.331.629–10.811.510
8 DOMINE 744.622 568.318–878.721 11.221.950 10.719.122–11.353.931
9 UniDomInt 863.228 667.232–1.019.495 11.541.609 10.635.969–11.826.811
10 PROSITE 256.028 221.618–276.509 10.967.586 10.962.602–11.560.607
11 Pfam 145.582 112.127–153.525 12.199.330 12.014.816–12.258.684
12 miRBase 342.756 275.376–347.322 10.136.253 9.243.720–10.163.274
13 miRNAmap 430.310 237.475–600.733 2.554.930 1.517.502–3.324.331
14 microRNA.org 228.423 148.857–350.045 2.025.078 1.410.494–2.800.161
15 TargetScan 422.876 242.981–656.470 5.420.278 3.766.078–6.798.828
doi:10.1371/journal.pone.0010225.t003
Figure 2. Global overview of the methodology. (A) In step 1, M secondary data sources are represented as a graph. The graph-related
information is subsequently incorporated via the pseudoinverse of the Laplacian (the G-matrix) into the calculation of patient similarity. In step 3, LS-
SVM models are built on each of the updated kernel matrices obtained in step 2. Based on a set of microarray training data, out of M secondary data
sources, r sources are selected that increase performance for all training data sets with respect to models built on only microarray data. (B) After
having selected the r outperforming secondary data sources, steps 1 to 3 are repeated for those r sources. In step 5, a classifier is learned and
constructed for the combination of the r corresponding LS-SVM models.
doi:10.1371/journal.pone.0010225.g002
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the Wilcoxon signed-ranks test to the average performance of all
data sets. The model based on the best individual secondary data
source outperformed the baseline models over all training data sets
(p-value 0.002). Also combining classifiers based on individual
secondary data sources with a fixed or trained rule outperformed
the baseline models with a p-value of 0.0039 and 0.0098,
respectively. The more advanced models did not perform
unambiguously better (p-value 0.557), although an improvement
was observed when reducing the number of classifiers.
To define the most optimal combination rules, we compared the
average performances for the fixed, trained and advanced
combination rules in Figures 4b to 4d, respectively. Based on the
training data sets, the mean fixed rule, the weighted trained rule
and naı ¨ve Bayes performed best. Only these three rules were
therefore validated on the remaining 6 microarray data sets.
Figure 5 and Table 6 show the validation results when considering
KEGG, OPHID and microRNA.org as secondary data sources.
The validation data sets confirm the training results: combining
the three individual models significantly improved classification in
4 out of 6 data sets, while no significant improvement was
obtained in 2 out of 6 data sets. Overall, the best individual
secondary data source, the mean fixed rule and the weighted
trained rule outperformed the baseline model with a p-value of
0.0313, 0.0313 and 0.0313, respectively. These higher p-values
compared to the results on the training data are due to the lower
number of validation data sets. When applying the Wilcoxon
signed-ranks test to all 16 considered data sets, the p-values
decreased to 0.0004, 0.0005 and 0.001, respectively. We can
therefore conclude based on the training and validation data sets
that averaging the predictions of the three classifiers performs best.
Weighting the predictions according to the training AUC values
does not provide additional value. The benefit of incorporating
secondary data sources was largest for data sets T1, V3 and V4
due to weaker experimental data caused by the limited number of
samples.
Discussion
In this manuscript, improved outcome prediction and classifi-
cation decision making have been made possible by incorporating
the human interactome in an LS-SVM model, chosen among a
large set of possible methods in which prior information can be
incorporated in the presented manner. Interactome data from
secondary data sources were encoded in a graph-based way and
used in similarity matrices for patient classification. Ten micro-
array data sets were randomly selected for training. For the
majority of these data sets, three secondary data sources increased
performance with respect to the baseline model based on
microarray data only, being KEGG, OPHID and microRNA.org.
The 15 secondary databases considered in this study could
therefore be reduced to three gene-related information sources
that are relevant across multiple cancer types with regard to the
considered class of models. These sources also showed a good
performance on 6 validation microarray data sets. With only three
models to combine, it could be shown on both training and
validation data sets that averaging the predictions of the individual
models suffices. The outstanding results of equally weighting the
individual models are in line with the findings of Lewis and
colleagues on kernel matrices [31]. They showed that for many
applications, a naive unweighted sum of matrices is sufficient
unless multiple noisy data sets are among the available data sets,
and that optimization of the weights is only beneficial when
sufficient data are available to more reliably estimate the weights.
Combination rules that require additional training are therefore
only expected to gain in importance when the sample size in
microarray studies increases.
The three selected sources KEGG, OPHID and microRNA.org
are the most complete databases for their type of information.
With the KEGG database, information about groups of genes
involved in the same metabolic pathways, pathways related to
genetic information processing, regulatory pathways or pathways
active in human diseases and drug development, is incorporated.
OPHID is a database on predicted interactions between human
proteins combining PPIs obtained from specialist literature, high-
throughput experiments, evolutionary conservation and other
databases such as BIND, HPRD and MINT. In the micro-
RNA.org database, predicted miRNA target sites are filtered
according to evolutionary conservation. This database was
represented as a network with links between genes that are
targeted by the same miRNA. Lu and colleagues [32] observed a
general down-regulation of miRNAs in tumors compared with
normal tissues. They were able to successfully classify poorly
differentiated tumors using miRNA expression profiles. The gene
expression profiles lacked this information when applied to the
same samples. An improved classification performance by
including the microRNA.org network in this study confirms the
importance of miRNAs in cancer and their impact on target genes.
The extra layer for the combination of classifiers is essential. For
verification, the largest network per type of gene-based informa-
tion, being KEGG, REACTOME, OPHID, STRING, PRO-
SITE and microRNA.org were pooled (that is, the edge weights
were added) before an LS-SVM model was built. However, in all
cases our 2-layer approach outperformed models built on a union
of secondary data sources. This emphasizes the specific edge
interpretation for each type of interaction and makes the
construction of individual models per secondary data source
essential before combining them at a second level.
In conclusion, we showed that it is possible to incorporate prior
information from secondary data sources in the form of the human
interactome in any kernel method or non-linear, kernel-based
extension of a non-kernel method. Any type of gene-related
information can be considered and the matrices derived from each
graph are representable in many different ways. Moreover, no part
of the data needs to be discarded. All genes are considered, also
Table 4. Selection of secondary data sources based on the
training microarray data sets.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
T1 14 9 0 11 10 0 0 13 15 12 0 8 0 0 0
T2 00001 4 0 1 5 00000000
T3 0001 4 1 5 0 00001 2 01 1 1 3 1 0
T4 1 5 0001 1 0 1 3 000001 2 1 4 0
T5 1 5 00000 1 1 000001 4 1 2 1 3
T6 1 4 1 3 001 5 0 0000001 2 00
T7 1 5 001 4 00 00000001 3 0
T8 01 3 0000 00000001 4 1 5
T9 701 2 01 5 9 1 0 1 4 01 1 0001 3 8
T10 00001 2 0 0001 5 001 4 1 3 0
Sum 80 35 12 39 92 94 92 71 53 81 28 6 392 46
Individual models with a better performance than the baseline model are given
a decreasing score starting from 15 for the best model; models that perform
worse are given the score 0.
doi:10.1371/journal.pone.0010225.t004
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no annotation is available. Our results show that for the
considered microarray technologies, cancer types and types of
outcome, integrating interactome data improves classification of
cancer outcome based on microarray data. This integration of
prior information in an SVM model based on gene expression
may benefit investigation of biological functionality.
Materials and Methods
Microarray data sets
An overview of the microarray data sets on breast, ovarian,
prostate cancer and large-B-cell lymphoma including at least 50
samples is provided in Table 2. For the data set of Bild [33], no
binary outcome was available. The median survival time of 3 years
was chosen as cut-off to balance both classes of samples. For the
data set of Rosenwald [34], the suggested 4 years was taken while
in the study by Wang [35], metastasis within 5 years was studied.
For these data sets, censored samples with last follow-up before the
chosen threshold (3, 4 or 5 years, respectively) were excluded,
resulting in the loss of 14, 20 and 10 samples, respectively.
The data sets gathered with the Affymetrix microarray
technology were preprocessed with MAS 5.0, the GeneChip
Microarray Analysis Suite 5.0 software (Affymetrix). An updated
array annotation was used for the conversion of probes to Entrez
Gene Ids [36]. A custom-designed microarray composed of genes of
which the products are preferentially expressed in lymphoid cells
was used in [34]. The data at the Entrez Gene level as provided by
the authors were therefore used. Missing gene expression values in
this data set were imputed unsupervised using the k-nearest
neighbors method [37], reducing the number of genes from 7399
to 6707. The parameter k was set to 15 such that a missing value for
a spot S in a sample was estimated as the weighted average of the 15
spots that are most similar to spot S in the remaining samples. We
also took the low signal-to-noise ratio of microarray data into
account by unsupervised exclusion of genes with low variation. The
Figure 3. Overall training results. Influence of secondary data sources and classifier combination on classification performance. The average test
AUC values under best training for 10 training microarray data sets, referred to as T1 to T10 are shown. Per training set, five bars are shown: 1) mean
AUC of the baseline model (blue); 2) mean AUC for the best individual secondary data source (KEGG, OPHID or microRNA.org) (cyan); 3) mean AUC for
the best fixed combination rule (green); 4) mean AUC for the best trained combination rule (orange); 5) mean AUC for the best advanced model
(brown). The secondary data source and combination rules that performed best and the p-values for the comparisons per training set are shown in
Table 5.
doi:10.1371/journal.pone.0010225.g003
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Data set model (combination) source/rule1 mean AUC (std)* p-valueu 2log(p)
T1 baseline 0.782 (0.113)
best individual KEGG 0.840 (0.100) 1.51e-25 24.82
best fixed rule mean 0.813 (0.105) 2.00e-17 16.70
best trained rule EXH 0.832 (0.104) 1.28e-20 19.89
best advanced rule LR 0.838 (0.105) 3.39e-12 11.47
T2 baseline 0.803 (0.081)
best individual OPHID 0.805 (0.078) 0.199 0.70
best fixed rule mean 0.808 (0.081) 0.0113 1.95
best trained rule W 0.808 (0.081) 0.0114 1.94
best advanced rule NB 0.806 (0.081) 0.125 0.90
T3 baseline 0.571 (0.073)
best individual OPHID 0.586 (0.078) 6.11e-5 4.21
best fixed rule median 0.576 (0.076) 0.0121 1.92
best trained rule W 0.575 (0.077) 0.089 1.05
best advanced rule LDA 0.550 (0.085) 0.999 0.00
T4 baseline 0.748 (0.088)
best individual KEGG 0.762 (0.085) 8.17e-7 6.09
best fixed rule median 0.765 (0.086) 7.30e-15 14.14
best trained rule W 0.764 (0.085) 1.87e-15 14.73
best advanced rule NB 0.764 (0.087) 3.40e-15 14.47
T5 baseline 0.727 (0.089)
best individual KEGG 0.736 (0.091) 0.000437 3.36
best fixed rule mean 0.737 (0.090) 6.02e-6 5.22
best trained rule W 0.737 (0.090) 8.77e-6 5.06
best advanced rule NB 0.734 (0.090) 0.000644 3.19
T6 baseline 0.645 (0.078)
best individual OPHID 0.653 (0.077) 9.73e-9 8.01
best fixed rule mean 0.650 (0.078) 2.74e-7 6.56
best trained rule W 0.650 (0.078) 3.27e-7 6.48
best advanced rule NB 0.647 (0.077) 0.0747 1.13
T7 baseline 0.929 (0.056)
best individual KEGG 0.942 (0.048) 6.02e-10 9.22
best fixed rule mean 0.937 (0.050) 2.27e-11 10.64
best trained rule W 0.937 (0.050) 3.45e-11 10.46
best advanced rule NB 0.937 (0.050) 1.36e-10 9.87
T8 baseline 0.584 (0.096)
best individual microRNA.org 0.587 (0.096) 0.156 0.81
best fixed rule median 0.581 (0.096) 0.785 0.10
best trained rule W 0.579 (0.093) 0.943 0.03
best advanced rule NB 0.565 (0.096) 0.999 0.00
T9 baseline 0.573 (0.110)
best individual OPHID 0.592 (0.117) 0.0151 1.82
best fixed rule mean 0.594 (0.113) 0.00842 2.07
best trained rule W 0.594 (0.113) 0.00787 2.10
best advanced rule NB 0.566 (0.117) 0.797 0.10
T10 baseline 0.680 (0.070)
best individual microRNA.org 0.691 (0.065) 0.0176 1.75
best fixed rule mean 0.688 (0.065) 0.0596 1.23
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genes to 5000 has the additional advantage that the computation of
the pseudoinverse Laplacian matrix remains tractable (see section
on the pseudoinverse Laplacian). Butthen again,theanalysis should
be performed on a sufficient number of genes between which
interactions are described in secondary data sources.
Figure 4. Training results per type of combination rule. Average test AUC values under best training for classifiers or combined classifiers,
each built on one of the outstanding secondary data sources KEGG, OPHID or microRNA.org for 10 training microarray data sets. (A) mean AUC
values for the individual classifiers, built on KEGG (blue), OPHID (green) or microRNA.org (brown); (B) mean AUC values for two fixed rules: mean
(blue) and median (green); (C) mean AUC values for three trained rules: weighted with the 5-fold training AUC values (W) (blue), weighted with the 5-
fold training AUC values scaled to ]0,1] (SW) (green) and exhaustive search among all possible combinations of 3 classifiers (EXH) (brown); (D) mean
AUC values for three more advanced models: naı ¨ve Bayes (NB) (blue), logistic regression (LR) (green) and linear discriminant analysis (LDA) (brown).
doi:10.1371/journal.pone.0010225.g004
Data set model (combination) source/rule1 mean AUC (std)* p-valueu 2log(p)
best trained rule SW 0.689 (0.065) 0.0419 1.38
best advanced rule NB 0.688 (0.066) 0.0586 1.23
1secondary data source or combination rule with the best performance (W=weighting according to the 5-fold training AUC values; SW=weighting with scaled 5-fold
training AUC values; EXH=exhaustive search among all possible combinations of 3 classifiers; NB=naı ¨ve Bayes; LR=logistic regression; LDA=linear discriminant
analysis).
*mean test AUC value under best training (standard deviation).
uone-sided paired-sampled t-test for the comparison with respect to the baseline model.
doi:10.1371/journal.pone.0010225.t005
Table 5. Cont.
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Metabolic pathways. Metabolic pathways were extracted
from four databases as each database may contain false positive
pathway predictions. Moreover, because most metabolic
reactions are linked with disease genes, the human metabolic
network is rather fragile [38]. The data source KEGG [23] stands
for Kyoto Encyclopedia of Genes and Genomes and is a
knowledge base for the analysis of gene functions in terms of
networks of genes and molecules. We focused on the KEGG
biochemical pathway database containing metabolic pathways,
pathways related to genetic information processing, regulatory
pathways involved in environmental information processing and
cellular processes, and pathways active in human diseases and
drug development. As the pathway information is matched with
the KEGG gene database, individual genes can be linked to
components of KEGG biochemical pathways. Based on these
cross-references, we extracted gene pairs defined as genes
encoding for proteins that can catalyze two reactions in the
same pathway.
Another large repository on metabolic pathways is BioCyc, a
collection of more than 350 organism-specific pathway/genome
databases (PGDBs) for most eukaryotic and prokaryotic species
with sequenced genomes [39]. Every BioCyc PGDB contains the
predicted metabolic network for one organism, including meta-
bolic pathways, enzymes, metabolites and reactions. These
databases can be divided into three groups, according to the
amount of manual curation. In this manuscript, we considered two
PGDBs, the intensively curated database MetaCyc [39] and the
computationally-derived database HumanCyc, subject to a
moderate curation of less than 1 year [40]. HumanCyc contains
information on 28783 human genes, their products and the
metabolic reactions and pathways they catalyze. The metabolic
pathways were predicted based on genome annotation, with
missing enzymes within the predicted pathways replaced by
candidate proteins when possible. MetaCyc [39], the Multi-
organism database of Metabolic Pathways and Enzymes provides
a high-quality resource on small-molecule metabolisms and
contains experimentally verified metabolic pathway and enzyme
Figure 5. Validation results for the optimal combination rules. Validation of the three selected secondary data sources and the best
performing combination rules on six new microarray data sets, referred to as V1 to V6. Per validation data set, five bars with the average test AUC
under best training are shown: 1) mean AUC of the baseline model (blue); 2) mean AUC for the best individual secondary data source (KEGG, OPHID
or microRNA.org) (cyan); 3) mean AUC for the fixed mean rule (green); 4) mean AUC for the weighted combination rule (orange); 5) mean AUC for the
naı ¨ve Bayes rule (brown). A numerical overview is given in Table 6.
doi:10.1371/journal.pone.0010225.g005
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human pathways from MetaCyc; however, only one metabolic
pathway was not included in HumanCyc. Gene pairs were defined
as genes with proteins belonging to the same metabolic pathway,
in analogy to KEGG.
Because not all known human metabolic pathways are included
in HumanCyc and KEGG, we also considered a more recent
human metabolic network, manually reconstructed by integrating
genome annotation information from different databases and
metabolic reaction information from specialist literature [38]. This
network, referred to as EHMN (Edinburgh human metabolic
network) contains more than 2000 metabolic genes and almost
3000 metabolic reactions, reorganized into 70 human-specific
metabolic pathways. Also here, gene pairs were defined as genes
encoding for enzymes that are involved in the same reaction.
The fourth secondary data source is REACTOME [24], an
expert-authored knowledge base of human biological processes.
The database consists of 2907 reactions involving 2975 human
proteins and grouped into pathways taking their temporal
relationships and interdependencies into account. It represents
pathways of intermediary metabolism, regulatory pathways, signal
transduction and high-level processes such as the cell cycle. Gene
pairs were defined as genes involved in the same reaction or
complex.
Protein-protein interactions. Next, several major databases
on PPIs are available. PPIs are typically extracted from
publications in which high-throughput proteomic or small-scale
biomolecular methods were applied. Especially high-throughput
methods make PPI networks noisy with many false positives and
inaccurate with inconsistent annotations. In addition, each
available PPI database uses its own extraction, curation and
storage protocols, they do not necessarily explore the same
scientific papers and are composed of different compositions of
experimentally and computationally determined interactions.
Prieto and De Las Rivas [41] have shown a limited intersection
and overlap between the six major PPI databases for human
proteins (BioGRID, BIND, MINT, HPRD, IntAct, DIP) [42–47].
As the information contained in these databases is partly
complementary, knowledge on the interactome can be increased
and improved by combining multiple databases. Notably, even the
union of all databases is still incomplete with many unknown
components and pathways, reaching coverage of 31% of the
human proteome, corresponding to 12053 proteins and 83670
interactions. The five largest databases are considered in this
contribution, with HPRD containing 63.3% of the known PPIs,
BioGRID 40.9%, IntAct 34.9%, MINT 22.5%, and BIND 9.7%
according to data in 2008 (see the ‘statistics’ section on http://
bioinfow.dep.usal.es/apid/, [41]). We did not consider DIP as this
database only contains 1.75% of the known PPIs [47]. Four of the
largest databases (BIND, HPRD, MINT and IntAct) are
combined with high-throughput experiments in the Online
Predicted Human Interaction Database (OPHID), a catalog of
60675 known human PPIs [25]. This manually-curated, literature-
derived catalog was further expanded with predictions for 34824
interactions that occur in other model organisms but with both
human orthologs conserved in humans. In this way, OPHID could
extend the human interactome with a set of proteins that have not
yet been included in literature-based databases. We translated all
biomolecules included in OPHID to one or multiple
corresponding genes, after which relations between the resulting
genes were extracted. The same definition for gene pairs was used
for the remaining PPI database BioGRID [42]. As this database is
multi-organismal, we only extracted the interactions between
human genes. The list of gene pairs for this database was much
Table 6. Performance of the three selected secondary data
sources (KEGG, OPHID, microRNA.org) and the combination
rule per type that performed best on the training data (mean,
AUC weighting (W) and naı ¨ve Bayes (NB)) for 6 validation
microarray data sets.
data set source/rule mean AUC (std) p-valueu 2log(p)
V1 baseline 0.741 (0.099)
KEGG 0.739 (0.097) 0.807 0.09
OPHID 0.734 (0.097) 0.982 0.01
microRNA.org 0.754 (0.101) 1.18e-7 6.93
mean 0.753 (0.096) 1.37e-7 6.86
W 0.752 (0.096) 3.13e-7 6.50
NB 0.750 (0.096) 3.37e-6 5.47
V2 baseline 0.610 (0.171)
KEGG 0.593 (0.154) 0.899 0.05
OPHID 0.627 (0.146) 0.0928 1.03
microRNA.org 0.610 (0.151) 0.509 0.29
mean 0.623 (0.147) 0.160 0.80
W 0.623 (0.148) 0.157 0.80
NB 0.595 (0.157) 0.864 0.06
V3 baseline 0.734 (0.225)
KEGG 0.770 (0.220) 2.27e-10 9.64
OPHID 0.723 (0.230) 0.979 0.01
microRNA.org 0.749 (0.224) 4.40e-4 3.36
mean 0.753 (0.225) 4.91e-6 5.31
W 0.753 (0.225) 5.10e-6 5.29
NB 0.737 (0.234) 0.380 0.42
V4 baseline 0.652 (0.189)
KEGG 0.688 (0.183) 5.11e-9 8.29
OPHID 0.630 (0.195) 0.999 0.00
microRNA.org 0.702 (0.180) 4.45e-17 16.35
Mean 0.682 (0.182) 4.55e-9 8.34
W 0.682 (0.182) 6.12e-9 8.21
NB 0.661 (0.182) 0.112 0.95
V5 baseline 0.667 (0.186)
KEGG 0.679 (0.180) 0.0128 1.89
OPHID 0.699 (0.176) 1.75e-6 5.76
microRNA.org 0.669 (0.187) 0.338 0.47
Mean 0.691 (0.180) 2.95e-7 6.53
W 0.692 (0.179) 1.55e-7 6.81
NB 0.678 (0.187) 0.0428 1.37
V6 baseline 0.604 (0.110)
KEGG 0.603 (0.109) 0.656 0.18
OPHID 0.618 (0.107) 0.00143 2.85
microRNA.org 0.611 (0.109) 0.00398 2.40
mean 0.607 (0.106) 0.196 0.71
W 0.607 (0.106) 0.185 0.73
NB 0.596 (0.114) 0.949 0.02
uone-sided paired-sampled t-test for the comparison with respect to the
baseline model.
doi:10.1371/journal.pone.0010225.t006
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gene had already been done by its curators.
STRING [48], the Search Tool for Recurring Instances of
Neighboring Genes, is extracted from PPI networks and
predictions based on comparative genomics and text-mining. It
lists potential functionally associated proteins based on the
genomic association of their genes. It thereby acts as a
metadatabase that maps all interaction evidence onto a common
set of genomes and proteins, by weighting and integrating
information from numerous sources: PPI databases, high-through-
put experimental interaction data, associations highlighted in
published literature, interaction transfer between organisms,
functional co-expression of genes, conserved neighborhood, gene
fusions and phylogenetic co-occurrences. All resulting individual
scores are integrated in a combined score, reflecting the
confidence for each predicted protein association. This results in
an increased confidence when an association is supported by
multiple types of evidence. We truncated the interaction network
to a stringency of 500 for the confidence score and only retained
gene interactions that were experimentally determined.
Domain-domain interactions. As often only a fraction of a
protein directly interacts with its biological partners, we also
investigated the use of inter-chain DDIs, that is, interactions
between domains from different proteins. To increase coverage
and quality, we considered two comprehensive resources that have
collated all known and predicted DDIs from various sources. The
database DOMINE [49] and the Unified Domain Interaction
database (UniDomInt) [50], both using Pfam-A domain
definitions, combine DDIs based on experimentally derived 3-
dimensional structures in the Protein Data Bank and DDIs
predicted by 8 and 9 computational approaches, respectively. In
the DOMINE database [49], each predicted DDI is given a
discrete confidence level high, medium or low. We did not include
the low confident DDIs that were only predicted by one
computational method, reducing the number of DDIs to 6689.
UniDomInt [50], on the other hand, provides a continuous
reliability score between 0 and 1. We set the minimal threshold to
0.1, including 8470 DDIs. Genes of which the proteins interact via
a domain-domain interaction were linked in the corresponding
graph representations.
Protein families and domains. To cover an as broad as
possible range of gene-related information, we additionally
investigated whether incorporating information on proteins
belonging to the same protein family or sharing the same
protein domain improves classification. Information on the
structural and functional properties of proteins was extracted
from the databases PROSITE [51] and Pfam [52]. PROSITE is a
database that uses amino acid patterns and profiles for the
identification of protein families, domains and functional sites. The
raw data provided by KEGG were used to extract gene pairs with
one or multiple protein domains, families or functional sites in
common. Pfam [52] is another large comprehensive and accurate
collection of protein domains and families. As a similar strategy
was followed as for PROSITE, no distinction could be made
between the manually curated Pfam A families and the
automatically generated Pfam B families. Also for Pfam, gene
pairs were defined as genes of which the proteins belong to the
same protein family or share the same protein domain.
Transcription factors. Finally, microRNAs (or miRNAs)
are a class of small non-coding RNA species with critical functions
across various biological processes by regulating gene expression.
Evidence has suggested that miRNAs may play a role in human
cancers [32]. We therefore defined gene pairs based on the
miRNAs by which they are regulated, using four available
microRNA databases. The miRBase (microRNA database) [53]
contains a pipeline for predicting miRNA target genes in mRNA
sequences based on the miRanda algorithm. P-values were
assigned to individual miRNA-target binding sites, connecting
each miRNA to a list of predicted gene targets. For the 851
miRNAs included in the database, we set the p-value to 0.001 to
include only the most confident predicted miRNA-target
assignments. MiRNAmap [54] is another database containing
470 miRNAs, dividable into known miRNA genes obtained from
miRBase and putative miRNA genes identified by comparative
sequence analysis. Besides experimentally verified miRNA targets
obtained from both specialist literature and TarBase [55], three
computational tools miRanda, RNAhybrid and TargetScan were
used for the identification of putative miRNA targets. To reduce
the rate of false positive target site predictions, we applied the three
criteria that were proposed by Hsu and colleagues [54]: target sites
must be predicted by at least two tools, they must be located in
accessible regions, and the target genes must contain multiple
target sites. Next, microRNA.org [56] contains target predictions
also based on the miRanda algorithm with miRNA sequences
obtained from miRBase, but the predicted target sites of 677
miRNAs were filtered according to evolutionary conservation of
sequence blocks across multiple vertebrates. We set the threshold
for the conservation score to 0.70 to select target sites that are
conserved in mammals. Finally, the target site prediction tool
TargetScan [57] provides a p-score, corresponding to a Bayesian
estimate of the probability that a site is conserved due to miRNA
targeting. These scores reflect the biological relevance and efficacy
of each site. We set the threshold to 0.3, corresponding to 74
miRNA genes. For all these databases, gene pairs were defined as
genes targeted by the same miRNA.
The programming language Perl was used for the conversion of
each secondary data source into a list of gene pairs, used as input
for the calculation of the pseudoinverse Laplacian.
Pseudoinverse Laplacian
Many biological processes are representable as a large-scale
sparse network. Each secondary data source, and more specifically
the list of extracted gene pairs, can therefore be represented as a
weighted, undirected graph with symmetric weights wkl§0,
assigned to each edge between a pair of different nodes k and l.
Such a graph is composed of p nodes representing the genes, and
the edges connect genes that are linked with regard to the
secondary data source under study. The graph is characterized by
a weighted adjacency matrix W=[wkl], k,l=1..p, and the diagonal
degree matrix D with degrees d1 to dp as diagonal elements. The
degree of a node k is defined as the sum of the weights wkl for node
k across all nodes l. From spectral graph theory, we can now define
the unnormalized graph Laplacian matrix L as the difference
between the degree matrix and the weighted adjacency matrix
(L=D2W). This matrix is symmetric and positive semidefinite.
Genes belonging to similar pathways will be connected by a
relatively large number of short paths, while fewer, typically longer
paths connect genes with completely separate functions. Finally, as
our aim is to add extra gene-related information with respect to
the traditional similarity measure rather than to discard genes for
which no information is available, self-loops were added to isolated
genes, setting their degree to 1.
Fouss and colleagues [30] have shown that the Moore-Penrose
pseudoinverse L
+ of the Laplacian matrix of a graph can be
interpreted in terms of similarity between pairs of genes in the
interacting network. Matrix entries increase when the number of
paths connecting two nodes increases and when the length of the
paths decreases. In this manuscript, we will present the pxp
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+ of the graph corresponding to
secondary data source m as Gm~½gkl  k,l~1::p. The graph of
each secondary data source and the extraction of Gm are presented
as step 1 in Figure 2. In case of a fully connected graph, the G-
matrix is expected to be fully dense. Isolated genes, however,
introduce zero patterns in the inverse, thereby reducing the density
as illustrated in Table 3. Other graph kernels such as the diffusion
kernel [58] are less suitable since they require an extra parameter
to be optimized. Also, instead of the unnormalized Laplacian, the
normalized version D
21/2LD
21/2 in which the connectivity of each
gene is taken into account can be considered as well. However, the
use of the normalized Laplacian did not lead to an improvement in
performance (results not shown).
Kernel methods and weighted Least Squares Support
Vector Machines
Kernel methods are a group of algorithms that can handle a
very wide range of data types such as vectors, sequences and
networks. They map the data x from the original input space to a
high dimensional feature space with the mapping function W(x).
This embedding into the feature space is performed by a kernel
function K(x
i,x
j). This function efficiently computes the inner
product SW(xi),W(xj)T between all pairs of data items x
i and x
j in
the feature space, resulting in the kernel matrix. The size of this
matrix is determined only by the number of data items, whatever
the nature or the complexity of these items. For example, a set of
100 patients each characterized by 5000 gene expression values is
still represented by a 100 x 100 kernel matrix [59]. The
representation of all data sets by this real-valued square matrix,
independent of the nature or complexity of the data to be
analyzed, makes kernel methods ideally positioned for heteroge-
neous data integration.
A kernel algorithm for supervised classification is the Support
Vector Machine (SVM) developed by Vapnik [60] and others.
Contrary to most other classification methods and due to the way
data are represented through kernels, SVMs can tackle high
dimensional data (for example microarray data). Given a training
set fxi,yig
N
i~1 of N samples with feature vectors xi [Rp and
output labels yi [f{1,z1g, the SVM forms a linear decision
boundary in the feature space y(x)~sign½wTW(x)zb  with
maximum margin between samples of the two considered classes,
with w representing the weights for the data items in the feature
space and b the bias term. This corresponds to a non-linear
discriminant function in the original input space. A modified
version of SVM, the Least Squares Support Vector Machine
(LS-SVM), was developed by Suykens and colleagues [27–28].
On high dimensional data sets, this modified version is
much faster for classification because a linear system of equations
instead of a quadratic programming problem needs to be
solved. The constrained optimization problem for an LS-SVM
has the following form: min
w,b,e
1
2
wTwzc
1
2
X N
i~1
e2
i
 !
subject to
yi½wTW(xi)zb ~1{ei i~1::N with ei the error variables
tolerating misclassifications in case of overlapping distributions,
and c the regularization parameter which allows tackling the
problem of overfitting. It has been shown that regularization is
very important when applying classification methods to high
dimensional data, even for linear classifiers [61].
In many two-class problems, data sets are skewed in favor of one
class such that the contribution to the performance assessment
criterion of false negative and false positive errors is not balanced.
We therefore used a weighted LS-SVM in which a different weight
fi is given to positive and negative samples, in order to account for
the unbalance in the data set [29]. The objective function changes
into: min
w,b,e
1
2
wTwzc
1
2
X N
i~1
fie2
i
 !
with fi~
N
2NP
if yi~z1
N
2NN
if yi~{1
8
> <
> :
and
NP and NN representing the number of positive and negative
samples, respectively.
Adapted kernel function
Any symmetric, positive semidefinite function is a valid kernel
function, resulting in many possible kernels - for example linear,
polynomial, and diffusion kernels. They all correspond to a
different transformation of the data, meaning that they extract a
specific type of information from the data set. In this paper, the
linear kernel function was investigated. Traditionally, a kernel
matrix based on a linear kernel function is represented as
K~XXT with X~½x1T
;...;xNT
  the Nxppatient microarray
data, N the number of samples, p the number of measured genes
(here, reduced to the 5000 most varying genes), and
T
representing the transpose of a vector or matrix. In patient
domain, each matrix entry Kij corresponds to xiT
xj,w i t hx
i and x
j
the gene expression profiles of samples i and j, respectively. We
incorporated a secondary G-matrix (introduced in the section on
the pseudoinverse Laplacian) in our kernel-based classification
framework by expanding the kernel matrix XXT to XGXT (step
2 in Figure 2). Each entry in this expanded kernel matrix now
corresponds to Kij~
P p
k,l~1
xi
kgklx
j
l. Each G-matrix thus exhaus-
tively relates the gene expression profiles of patients, weighted by
its entries gkl. As each secondary data source leads to a different
kernel matrix, normalization is required to make them compa-
rable. The normalized kernel matrix ~ K K was therefore considered,
defined as K=trace(K) with trace(K) the sum of the diagonal
elements of K.
Combining classifiers
It is not known beforehand which secondary data sources are
relevant for the problem at hand and thus which of the sources will
increase prediction accuracy. The predictions of the LS-SVM
models, each built with the inclusion of one secondary data source,
were therefore combined at a second level (step 5 in Figure 2).
Duin and Tax [62] have shown that no combining rule is optimal
in multiple combination tasks. We therefore considered multiple
combination schemes that have proven to be useful in specialist
literature and that provide continuous predictions on which the
AUC can be calculated. A comparison of AUC values is less
sensitive to the specific cut-off level used for assigning observations
to different classes.
A distinction is made between fixed and trained combining
rules [62–63]. As fixed combining rules, we investigated mean
and median. Although the mean or sum rule assumes
independent classifiers, it may also work for similar classifiers
with independent noise behavior, thereby reducing the error on
the estimated output values. The same holds for the median rule,
likely to yield more robust results in comparison to the mean rule.
Fixed combining rules, however, are almost always suboptimal
while a trainable combiner may lead to a more significant
improvement with respect to static combiners [63]. Moreover,
statistically independent classifiers are not required when a linear
or non-linear combiner is trained [64]. Although requiring
additional data and at the cost of additional training, a weighted
sum of the predictions of the individual classifiers was considered.
The weights were set to the raw training AUC values or to these
values after scaling to the half-open interval ]0,1]. Furthermore,
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tions of individual classifiers was performed. We additionally
considered three more advanced models, being naı ¨ve Bayes (NB),
logistic regression (LR) and linear discriminant analysis (LDA).
Both NB and LDA are ideal methods when the number of
training observations is limited. Although NB is based on the
assumption of independence between predictors, a good perfor-
mance has been shown for functional dependencies, that is,
predictors that are generated from the same underlying
distribution [65]. This is likely to be the case in this set-up as
the latent variables are obtained from the same microarray data
set, modified by a specific secondary data source.
Model building
In this study, each data set was split into 10 folds, stratified to
outcome. 50% of the data corresponding to folds 1 to 5 was used
for training the individual classifiers. This part of the data was
normalized per gene, and the obtained gene characteristics were
used for normalization of folds 6 to 10. An internal 5-fold cross-
validation on folds 1 to 5 was used for the optimization of the
regularization parameter c. Forty possible values for c ranging
from 10
24 to 10
6 were considered on a logarithmic scale. The
final model parameter was chosen corresponding to the model
with the highest AUC. In case multiple models had the same
AUC, the model with the lowest balanced error rate and an as
high as possible sum of sensitivity and specificity was chosen. An
LS-SVM model was rebuilt on the entire training data with the
optimal regularization parameter and applied to the remaining
50% of the data. Similar results were obtained when the L-curve
was used for the selection of c [66]. As the c values of the
individual LS-SVM models were checked cautiously to prevent
overfitting and to assure good generalization performance, the
combining rules were learnt on 80% of the data of which 30%
(that is, folds 6 to 8) were new with respect to the first training
phase. Considering 80% of the data in the second phase for
training a combined classifier has the extra advantage that the
peaking phenomenon is countered, defined as the decrease in
classification accuracy when too many features are included in
the classifier [67]. Among the considered combined classifiers,
especially LDA suffers from this phenomenon [68]. LDA is also
poorly posed when the number of observations and parameters to
be estimated is comparable [69]. The use of 80% of the data
guarantees that the number of training observations sufficiently
exceeds the number of individual classifiers. The last 2 folds
corresponding to 20% of the data were used for validation. Not
only the combined classifiers but also the baseline LS-SVM
model built only on the microarray data and the models with the
individual use of each of the secondary data sources were
validated on the same observations. To reduce the random
variation in the selection of training and test data, the split of the
data into 10 folds was repeated 200 times. A comparison of the
AUC values was performed between the baseline model and all
other models using the one-sided paired-sampled t-test. However,
the overlap in training and test set between the 200 experiments
can increase the probability of type I errors (that is, rejecting a
true null hypothesis). Moreover, we are not only interested in the
performance for a specific problem, but rather in the general
performance on multiple data sets. The obtained results per data
set were therefore confirmed by repeating the comparisons over
all data sets with the average performance per set, using the non-
parametric Wilcoxon signed-ranks test [70].
Out of the 16 microarray data sets, 10 were randomly selected
for training indicated with the symbol T in Table 2. These 10 data
sets were used to determine the secondary data sources that
improved performance compared to the baseline model in the
majority of data sets. These data sets were subsequently used to
define which of the combination rules performed best. The set of
the best rules was applied to 6 validation microarray data sets
indicated with the symbol V in Table 2.
To assess the dependency between individual LS-SVM models,
we considered mutual information (MI) [71]. When two random
variables x and y have probability distributions P(x) and Q(y),
mutual information I is defined as the relative entropy between the
joint distribution R(x,y) and the product distribution P(x)Q(y):
I(x,y)~
P
x,y R(x,y)log2(R(x,y)=½P(x)Q(y) ). Mutual informa-
tion is a measure of the reduction in uncertainty about one
variable given the other, meaning that variables are statistically
independent when MI=0. A higher MI indicates that the two
variables are non-randomly associated with each other [71]. In
this study, the variables x and y are binary and defined as 1 with
the classifier predicting a sample being of the positive class and 0
otherwise.
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